Michael Szarek

Aug 26, 2023 | ahajournals.org | Michael Szarek |J. Wouter Jukema |Deepak L. Bhatt |Esther Reijnders

Background: Lipoprotein(a) is a risk factor for cardiovascular events and modifies the benefit of pcsk9 inhibitors (pcsk9i). Lipoprotein(a) concentration can be measured with immunoassays reporting mass or molar concentration or a reference measurement system employing mass spectrometry. Whether the relationships between lipoprotein(a) concentrations and cardiovascular events in a high-risk cohort differ across lipoprotein(a) methods is unknown.

Aug 26, 2023 | ahajournals.org | Michael Szarek |Esther Reijnders |J. Wouter Jukema |Deepak L. Bhatt

Clinical PerspectiveIn patients with recent acute coronary syndrome, we compared 2 immunoassay-based tests that report mass and molar lipoprotein(a) concentration with a mass spectrometry–based test that reports molar apolipoprotein(a) concentration in relation to major adverse cardiovascular event (MACE) risk and reduction of this risk with the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor alirocumab.

Aug 1, 2023 | jacc.org | Bertram Pitt |Deepak L. Bhatt |Michael Szarek |Christopher Cannon

IntroductionHeart failure (HF) is the second most common cause of hospitalizations for patients >65 years of age in the United States, posing a significant cost burden on society.1,2 The morbidity and mortality impact on patients is also severe.